Loading clinical trials...
Loading clinical trials...
Phase IB/II Study of Enzalutamide With Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression
Conditions
Interventions
Enzalutamide
Ribociclib
+9 more
Locations
4
United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Start Date
December 1, 2015
Primary Completion Date
December 7, 2022
Completion Date
September 1, 2023
Last Updated
April 22, 2026
NCT04693377
NCT06526299
NCT04550494
NCT06705686
NCT06305598
NCT04489719
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions